Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7255 results

Sort By:

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Study ID: NCT04764357
Start Date: 2021-06-04
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Paxman Scalp Cooling System

Alopecia Assessments

Patient Reported Outcomes Questionnaires

Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

Study ID: NCT06542757
Start Date: 2024-12-09
End Date: 2027-11
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

91

Intervention / Treatment

1.5 T Elekta Unity MR-Linac system

Hydrogel rectal spacer (SpaceOAR)

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list

Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation

Study ID: NCT06298357
Start Date: 2024-06-27
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

16

Intervention / Treatment

Immediate Start - Virtual Reality

Delayed Start - Virtual Reality

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Study ID: NCT06399757
Start Date: 2024-06-18
End Date: 2027-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

APL-5125

Sponsor

Apollo Therapeutics Ltd

Source: clinicaltrials.gov

Share:
Add to list

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

Study ID: NCT04523857
Start Date: 2021-11-01
End Date: 2028-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

66

Intervention / Treatment

Abemaciclib

Hydroxychlorine

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Study ID: NCT06941857
Start Date: 2025-08
End Date: 2030-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Oxaliplatin

Irinotecan

Folinic Acid

5-Fluorouracil (5-FU)

NC410

Nivolumab

Ipilimumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Study ID: NCT04071457
Start Date: 2019-08-13
End Date: 2040-07-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1100

Intervention / Treatment

Lenalidomide

Daratumumab/rHuPH20

Sponsor

SWOG Cancer Research Network

Source: clinicaltrials.gov

Share:
Add to list

Intraoral Hypothermia Device for Preserving Taste During Radiation

Study ID: NCT06579248
Start Date: 2024-11-12
End Date: 2025-08-30
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

15

Intervention / Treatment

Intraoral Device

Sponsor

Henry Ford Health System

Source: clinicaltrials.gov

Share:
Add to list

Doxycline in Cutaneous Swannoma (NF2)

Study ID: NCT05521048
Start Date: 2022-09-19
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

19

Intervention / Treatment

Doxycycline Injection [Doxy]

Sponsor

Massachusetts Eye and Ear Infirmary

Source: clinicaltrials.gov

Share:
Add to list

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Study ID: NCT06561048
Start Date: 2024-10-02
End Date: 2028-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

150

Intervention / Treatment

Duplicated

Whiteness

Pralatrexate

Sponsor

Corvus Pharmaceuticals, Inc.

Source: clinicaltrials.gov

Share:
Add to list